32 unknown, 11 recruiting, 8 not yet recruiting, 6 active not recruiting. 34 Phase 2, 17 Phase 3, 9 Phase 1, 4 Not applicable, 1 Phase 4.
Follow aumolertinib: new trials by email Literature Review of aumolertinib trials Research Report on aumolertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC Aumolertinib, Pemetrexed, Carboplatin - Non-Small Cell Lung Cancer | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-11-01 | 2026-10-14 |
| An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 660 | 2026-10-30 | 2026-11-09 |
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC SHR-A2009 ; Aumolertinib, Aumolertinib - Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 582 | 2025-10-30 | 2026-09-25 |
| A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC BL-B01D1, Almonertinib - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan University | 40 | 2025-06-25 | 2025-07-23 |
| A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations Almonertinib, Palbociclib - EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 71 | 2025-06-09 | 2025-06-04 |
| Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer Aumolertinib, Osimertinib - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 316 | 2024-12-17 | 2024-12-30 |
| A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer Aumolertinib - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 20 | 2024-12-05 | 2025-08-19 |
| AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) - NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases | Recruiting | Fudan University | 800 | 2024-09-30 | 2024-11-12 | |
| Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 91 | 2024-06-01 | 2024-06-11 |
| Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). Aumolertinib - Lung Cancer | Phase 2 | Withdrawn | Sun Yat-sen University | 2024-06-01 | 2024-12-10 | |
| Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer Almonertinib - Lung Cancer Non-small Cell Stage IV | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 60 | 2024-06-01 | 2024-06-17 |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer HS-20117, Aumolertinib - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Hansoh BioMedical R&D Company | 1080 | 2024-05-28 | 2025-08-01 |
| Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC almonertinib, Carboplatin, Nab paclitaxel - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Active not recruiting | Guangdong Provincial People's Hospital | 32 | 2024-04-01 | 2026-04-29 |
| RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations Disitamab Vedotin, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib - Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 108 | 2024-02-01 | 2023-12-29 |
| A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation Combined therapy of anlotinib and aumolertinib - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Not applicable | Recruiting | Kunming Medical University | 30 | 2023-10-30 | 2023-10-26 |
| Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer Almonertinib - Lung Cancer Stage III | Phase 2 / Phase 3 | Unknown | Laibin People's Hospital | 40 | 2023-09-01 | 2023-08-29 |
| Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance almonertinib - Advanced Non-small Cell Lung Cancer | Phase 3 | Recruiting | Qianfoshan Hospital | 98 | 2023-09-01 | 2023-09-21 |
| Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. Aumolertinib - Lung Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 22 | 2023-08-15 | 2024-02-06 |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation Aumolertinib,Anlotinib - Aumolertinib, Anlotinib | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 47 | 2023-03-31 | 2023-03-21 |
Showing 20 of 63. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (37) · Lung Neoplasms (12) · Brain Neoplasms (5) · Meningeal Carcinomatosis (2) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Liver Diseases (1) · Neoplasm, Residual (1) · Radiation Pneumonitis (1) · Recurrence (1)
Jiangsu Hansoh Pharmaceutical Co., Ltd. (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Sun Yat-sen University (4) · Fudan University (3) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (3) · EQRx International, Inc. (2) · First People's Hospital of Hangzhou (2) · Fujian Cancer Hospital (2) · Qianfoshan Hospital (2) · Shanghai Cancer Hospital, China (2) · Shanghai Chest Hospital (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · The First Affiliated Hospital of Guangzhou Medical University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Baohui Han (1)
China (49) · United States (4) · Bosnia and Herzegovina (1) · Bulgaria (1) · Moldova (1) · New Zealand (1)
Likun Chen (2) · Shun Lu, MD (2) · Ying Cheng, MD (2) · Bin Wang (1) · Chun Huang (1) · Chunxia Su (1) · Conghua Xie (1) · Degan Lu (1) · Dingzhi Huang (1) · Dingzhi Huang, M.D. (1) · Fei J Zhu (1) · Feng Luo (1)
PMID 32916310, PMID 15118073, PMID 15118125, PMID 15886314, PMID 16642476, PMID 19470276, PMID 20087963, PMID 20573926, PMID 24002608, PMID 25175099, PMID 26334749, PMID 27539328, PMID 29190637, PMID 29446853, PMID 29454091, PMID 30017884, PMID 30032842, PMID 30039345, PMID 30059262, PMID 30098152, PMID 30666799, PMID 30975627, PMID 31591063, PMID 31809241, PMID 31865717, PMID 33205587, PMID 33544337, PMID 33962566, PMID 34083331, PMID 34388377, PMID 35580297, PMID 39016053, PMID 40306921, PMID 40569623, PMID 41326640, PMID 41510386, PMID 41539318, PMID 41818162, PMID 42296979, PMID 42488708